Cancer, Hypoxia, and Metabolism

SEP 8, 2026 · JOURNAL ARTICLE

Effects of Lactylation in Cancer Progression

Theoretical and Natural Science

A narrative review of mechanistic pathways linking protein lactylation to cancer phenotypes; raises questions about therapeutic potential but reports no empirical data, effect sizes, or clinical outcomes.

SEP 7, 2026 · JOURNAL ARTICLE

Cu-deficient Cu–Fe Prussian blue analogues enable phosphate/GSH-coupled redox remodeling for catalytic/sonodynamic cancer therapy

Journal of Nanobiotechnology

Early-stage preclinical study demonstrating a novel nanoparticle design in cell culture and a single murine tumor model, without clinical translation, efficacy comparators, or mechanistic validation beyond correlative evidence.

SEP 7, 2026 · JOURNAL ARTICLE

Reprogramming the Tumor Microenvironment and Cancer Therapy via Nanocatalytic Medicine

Acs Nano Medicine

A narrative review proposing nanocatalytic medicine as a conceptual paradigm for TME modulation in cancer, without original experimental data, clinical trials, or quantitative evidence of efficacy or safety.

SEP 7, 2026 · JOURNAL ARTICLE

Glucose-induced histone lactylation confers metformin resistance in colorectal cancer stem cells

Nature Communications

A mechanistic study identifying a metabolic pathway and proposing drug targets, but without clinical efficacy data, human trials, or validation of the proposed combination therapy.

SEP 7, 2026 · JOURNAL ARTICLE

PSMD14 as a translational target in cancer and beyond: from deubiquitination mechanisms to drug resistance and precision therapy

Cancer Drug Resistance

This is a narrative review synthesizing preclinical mechanistic evidence and proposing PSMD14 as a therapeutic target, but it does not report new empirical data, clinical trials, or outcomes in patients.

SEP 4, 2026 · JOURNAL ARTICLE

Lipid metabolic reprogramming in NSCLC: mechanisms, microenvironment crosstalk, and therapeutic opportunities

Journal of Translational Medicine

A phase 1 study reporting a preliminary signal of activity in a molecular subtype (KRAS-mutant NSCLC, n=11) with a small sample, surrogate endpoint (progression-free status at 12 weeks), and no established clinical efficacy in unselected patients.

SEP 4, 2026 · JOURNAL ARTICLE

A Locally Injectable, pH/ROS-Responsive Hydrogel Platform for Combination Therapy of Cervical Cancer with Anti-Fibrotic and Chemotherapeutic Agents

Pharmaceutics

Early-stage preclinical work demonstrating proof-of-concept in cell culture and mouse models; no clinical efficacy data, human trials, or comparison to standard cervical cancer therapy reported.

AUG 19, 2026 · JOURNAL ARTICLE

Hypoxia-responsive soft biohybrid bacteria for breast cancer therapy

Soft Science

This is a mechanistic proof-of-concept describing a novel biohybrid system design with no reported clinical or in vivo efficacy data, animal studies, or human trials to support therapeutic claims.